What Is NewAmsterdam Pharma Company N.V (NAMSW) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, NewAmsterdam Pharma Company N.V's intrinsic value is estimated at $5.97. Trading at its current price of $20.56, the valuation engine raises significant caution: 8 of 8 models flag downside risk, projecting an average implied return of -71.0%. The most optimistic model, FTNN, places fair value at $14.63 (-28.8%), while Regime Cross — the most conservative — estimates $0.43 (-97.9%). This +69.1% gap reflects genuine analytical uncertainty about NewAmsterdam Pharma Company N.V's intrinsic worth.
What Do the Models Say About NAMSW?
8 of 13 models are currently active for NAMSW. All 8 active models suggest the stock trades above fair value. See which stocks rank higher →
How Does NAMSW Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, NAMSW ranks #394 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
NewAmsterdam Pharma Company N.V's positioning within the Pharmaceutical Preparations segment means that R&D productivity ratio plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.
Is NAMSW a Value Trap?
The Value Trap algorithm is not active for NAMSW. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for NewAmsterdam Pharma Company N.V. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, NewAmsterdam Pharma Company N.V scores 2.5 out of 10 on our 32-signal quality assessment, a weak rating that exhibits fundamental weaknesses that warrant careful scrutiny. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +69.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every NAMSW valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across NAMSW's 8 active models, average confidence is 24%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad